Accurate medicine: Indirect targeting of NPM1-Mutated AML

Christopher S. Hourigan, Peter D. Aplan

Research output: Contribution to journalArticlepeer-review


Acute myeloid leukemia (AML) is now recognized to be an imprecise term that refers to a range of myeloid malignancies that have different genetical etiologies, clinical characteristics, and therapeutic sensitivities. Targeting the MLL1 and DOT1L histone modification complexes, both alone and in combination, showed activity against AML driven by a mutant NPM1 protein in several preclinical models and may represent a new treatment direction for this devastating disease.

Original languageEnglish (US)
Pages (from-to)1087-1089
Number of pages3
JournalCancer discovery
Issue number10
StatePublished - Oct 2016
Externally publishedYes

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Accurate medicine: Indirect targeting of NPM1-Mutated AML'. Together they form a unique fingerprint.

Cite this